Mibampator

From WikiMD's WELLNESSPEDIA

Mibampator (also known as LY451395) is an Ampakine compound developed by Eli Lilly and Company for potential use in the treatment of Alzheimer's disease and cognitive disorders. It is a positive allosteric modulator of the AMPA receptor, which is involved in synaptic transmission in the brain.

History[edit]

Mibampator was first synthesized and developed by Eli Lilly and Company, a global pharmaceutical company. The compound was part of a larger research effort into Ampakines, a class of compounds that enhance the function of the AMPA receptor.

Mechanism of Action[edit]

Mibampator works by enhancing the function of the AMPA receptor, a type of ionotropic glutamate receptor that mediates fast synaptic transmission in the brain. It is a positive allosteric modulator, meaning it binds to a site on the receptor different from the active site and enhances the receptor's response to its ligand, glutamate. This is thought to enhance cognitive function and potentially slow the progression of neurodegenerative diseases like Alzheimer's disease.

Clinical Trials[edit]

Mibampator has undergone several clinical trials to assess its safety and efficacy in treating cognitive disorders. In Phase II trials, it was found to be safe and well-tolerated, but did not show significant improvement in cognitive function in patients with mild to moderate Alzheimer's disease. Further research is needed to fully understand the potential therapeutic benefits of Mibampator.

See Also[edit]

References[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


  • Mibampator
    Mibampator

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Mibampator&oldid=6335716"